The Technical Analyst
RepliCel Life Sciences [REPCF]
Exchange: PNK Industry: Biotechnology
RepliCel Life Sciences Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0428
America/New_York / 15 mar 2024 @ 11:20
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2.78 mill |
| EPS: | -0.0100 |
| P/E: | -4.28 |
| Earnings Date: | May 30, 2024 |
| SharesOutstanding: | 65.00 mill |
| Avg Daily Volume: | 0.0025 mill |
| RATING 2024-03-15 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.28 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -4.28 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0348 - 0.0508 ( +/- 18.68%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0428 (0.00% ) |
| Volume | 0.0006 mill |
| Avg. Vol. | 0.0025 mill |
| % of Avg. Vol | 22.34 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For REPCF
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
REPCF
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Latest Press Releases
2021-10-18 06:00:00 - Press Release
Replicel Files Notice Of Arbitration Against Shiseido Company To Resolve Its License Agreement Dispute Regarding Its Androgenetic Alopecia Cell Therapy
After several unsuccessful attempts to settle the dispute, replicel has filed an arbitration claim seeking shiseido's full compliance with the agreement or return of the license and all collaboration data and innovations related to its cell therapy treatment for male and female pattern hair loss. vancouver, bc / accesswire / october 18, 2021 / replicel life sciences inc. (otc pink:repcf)(tsxv:rp)(fra:p6p2) ("replicel" or the "company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has retained aceris law llc, a law firm specialized in international arbitration, to pursue the resolution of its disagreement with shiseido company limited ("shiseido").
2021-10-12 06:00:00 - Press Release
Replicel Life Sciences Appoints One Of Japan's Foremost Regenerative Medicine Industry Business Leaders As Strategic Advisor
Kunihiko suzuki, one of the leading pioneers in japan's emerging regenerative medicine industry, commits to a role as senior strategic advisor to replicel's board of directors vancouver, bc / accesswire / october 12, 2021 / replicel life sciences inc. (otc pink:repcf)(tsxv:rp)(fra:p6p2) ("replicel" or the "company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that kunihiko suzuki has agreed to accept an appointment as a senior strategic advisor to its board of directors with a particular focus on building the company's enterprise in japan. "we are delighted to have someone of mr.
2021-09-16 06:00:00 - Press Release
Replicel And University Of Victoria Collaboration Leads To Bioengineering Innovations, Funding, And Patents
Canadian granting agency mitacs commits to three years of funding for the project's second stage to optimize certain proprietary microcarrier technologies for use in replicel's cell therapy manufacturing replicel signs an option to license agreement related to a filed us patent application vancouver, bc / accesswire / september 16, 2021 / replicel life sciences inc. (otcqb:repcf)(tsxv:rp)(fra:p6p2) ("replicel" or the "company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that the first-stage of a research project with the university of victoria centre for biomedical engineering ("uvic") has led to significant milestones in terms of technology advancements, patent filings, grant funding, and a license option agreement...
2021-07-07 06:00:00 - Press Release
Replicel Applies For Manufacturing Approval For Its Collagen And Tissue Regeneration Cell Therapies
Clinical development of replicel's skin rejuvenation and tendon regeneration injectables continues to meet milestones on path to commercialization in japan vancouver, bc / accesswire / july 7, 2021 / replicel life sciences inc. (otc pink:repcf)(tsxv:rp)(fse:p6p2) ("replicel" or the "company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has submitted its application to japan's ministry of health, labour, and welfare (mhlw) for approval to manufacture the company's rct-01 cell therapy for chronic tendinopathy and rcs-01 cell therapy for aging and sun-damaged skin for its upcoming clinical studies. with successful phase 1 studies complete, replicel is currently preparing for clinical research of its skin rejuvenation (rcs-01) and tendon regeneration (rct-01) cell therapies in japan under the act for safety of regenerative medicine (asrm) which, upon successfully meeting its endpoints, could lead to the commercial launch of the products in japan.
2021-06-15 06:00:00 - Press Release
Replicel Adds Independent Director
Board of directors strengthens its independence oversight and updates its stock options vancouver, bc / accesswire / june 15, 2021 / replicel life sciences inc. (otcqb:repcf)(tsxv:rp)(fra:p6p2), (“replicel” or the “company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has appointed gary boddington to the board of directors. gary boddington is currently the ceo of playwize technology inc. he is experienced in founding and leading global companies, exploring new markets, launching new products, and raising capital.
Latest News
2021-10-18 06:00:00 - Accesswire
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy
After several unsuccessful attempts to settle the dispute, RepliCel has filed an arbitration claim seeking Shiseido's full compliance with the agreement or return of the license and all collaboration data and innovations related to its cell therapy treatment for male and female pattern hair loss. VANCOUVER, BC / ACCESSWIRE / October 18, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has retained Aceris Law LLC, a law firm specialized in international arbitration, to pursue the resolution of its disagreement with Shiseido Company Limited ("Shiseido").
2021-10-12 06:00:00 - Accesswire
RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
Kunihiko Suzuki, one of the leading pioneers in Japan's emerging regenerative medicine industry, commits to a role as Senior Strategic Advisor to RepliCel's Board of Directors VANCOUVER, BC / ACCESSWIRE / October 12, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that Kunihiko Suzuki has agreed to accept an appointment as a Senior Strategic Advisor to its Board of Directors with a particular focus on building the Company's enterprise in Japan. "We are delighted to have someone of Mr.
2021-09-16 06:00:00 - Accesswire
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
Canadian granting agency MITACS commits to three years of funding for the project's second stage to optimize certain proprietary microcarrier technologies for use in RepliCel's cell therapy manufacturing RepliCel signs an Option to License agreement related to a filed US patent application VANCOUVER, BC / ACCESSWIRE / September 16, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that the first-stage of a research project with the University of Victoria Centre for Biomedical Engineering ("UVic") has led to significant milestones in terms of technology advancements, patent filings, grant funding, and a license option agreement...
2021-07-07 06:00:00 - Accesswire
RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies
Clinical development of RepliCel's skin rejuvenation and tendon regeneration injectables continues to meet milestones on path to commercialization in Japan VANCOUVER, BC / ACCESSWIRE / July 7, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FSE:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has submitted its application to Japan's Ministry of Health, Labour, and Welfare (MHLW) for approval to manufacture the Company's RCT-01 cell therapy for chronic tendinopathy and RCS-01 cell therapy for aging and sun-damaged skin for its upcoming clinical studies. With successful phase 1 studies complete, RepliCel is currently preparing for clinical research of its skin rejuvenation (RCS-01) and tendon regeneration (RCT-01) cell therapies in Japan under the Act for Safety of Regenerative Medicine (ASRM) which, upon successfully meeting its endpoints, could lead to the commercial launch of the products in Japan.
2021-06-15 06:00:00 - Accesswire
RepliCel Adds Independent Director
Board of Directors Strengthens Its Independence Oversight and Updates its Stock Options VANCOUVER, BC / ACCESSWIRE / June 15, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2), (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has appointed Gary Boddington to the board of directors. Gary Boddington is currently the CEO of PlayWize Technology Inc. He is experienced in founding and leading global companies, exploring new markets, launching new products, and raising capital.
2021-05-19 06:00:00 - Accesswire
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies
Clinical Research Organization, Accerise Inc., Has Been Retained To Work With RepliCel and Its Other Service Providers To Prepare Study Documentation, Plans, and Approvals for Clinical Evaluation by Multiple Clinical Sites in Japan VANCOUVER, BC / ACCESSWIRE / May 19, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it has retained leading clinical research organization, Accerise Inc, with offices in Tokyo and Osaka, to lead the planning and preparations for clinical research studies of RepliCel's skin rejuvenation (RCS-01) and tendon regeneration (RCT-01) cell therapy products in Japan...
2021-05-05 06:00:00 - Accesswire
RepliCel Announces Record Year in Patents Granted
Patents Granted in the United States, China, South Korea, Japan, Israel and New Zealand for Dermal Injector and Tendon Regeneration Technologies VANCOUVER, BC / ACCESSWIRE / May 5, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation regenerative medicine technologies in aesthetics and orthopedics, is pleased to announce the granting and/or allowance of seven patent applications since December 2020. The two patent families involved are REPL 403 related in the RepliCel dermal injector and REPL 407 related to compositions and methods for treating and repairing tendons.
2021-05-03 06:00:00 - Accesswire
RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan)
Professor Tsukasa Kumai, member of the Japan's Olympic Committee Medical and Scientific Staff, will lead RepliCel's Tendon Regeneration Clinical Testing in Japan VANCOUVER, BC / ACCESSWIRE / May 3, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that Professor Tsukasa Kumai, one of Japan's leading sports medicine clinicians, has agreed to be RepliCel's clinical advisor for the development and commercialization of its tendon regeneration product (RCT-01) in Japan. The Company, working with industry leaders, CJ Partners, and clinical research organization, Accerise, is currently preparing to support the next-phase clinical research study of its tendon regeneration cell therapy, RCT-01, in Japan under the Act for Safety of Regenerative Medicine (ASRM) that, upon successfully meeting its endpoints, could lead to a commercial launch of the product in Japan.
2021-04-29 06:00:00 - Accesswire
RepliCel Closes Second Tranche of Strategic Investment Commitment
MainPointe Pharmaceuticals Completes Largest Scheduled Share Purchases per Investment Agreement VANCOUVER, BC / ACCESSWIRE / April 29, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has closed the second tranche of the investment by MainPointe Pharmaceuticals ("MainPointe") as outlined in the share purchase agreement signed earlier this year by the parties. This second tranche involved MainPointe's purchase of 1,777,778 common shares issued by RepliCel in exchange for CAD $1,200,000 which has now been received by the Company.
2020-11-10 06:00:00 - GlobeNewsWire
RepliCel Announces a Binding Term Sheet For Strategic Investment and U.S. Partnership
VANCOUVER, British Columbia, Nov. 10, 2020 (GLOBE NEWSWIRE) -- RepliCel Life Sciences Inc. (OTC PK : REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, announced today its intent to enter into a strategic partnership with MainPointe Pharmaceuticals (“MainPointe”) headquartered in Louisville, Kentucky.